Publication | Closed Access

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

MedicineMelanomaIpilimumab 10Clinical TrialsMetastatic MelanomaImmune Checkpoint InhibitorPharmacotherapyDermatologyCancer TreatmentOncologyPhase 3